Sign In
Buy APTX
$0.0960
+0 (+0%)
At Close: Mar 28, 2024
Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
04:10pm, Tuesday, 15'th Jun 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announ
Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?
01:14pm, Friday, 11'th Jun 2021
Top growth penny stocks to watch this year? Check these 3 out right now The post Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2021 Results - Earnings Call Transcript
11:10pm, Thursday, 13'th May 2021
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2021 Results - Earnings Call Transcript
Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week
01:22pm, Saturday, 24'th Apr 2021
5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | Penn
Aptinyx Stock Price Increased Over 4% Pre-Market: Why It Happened
07:19am, Tuesday, 06'th Apr 2021
The stock price of Aptinyx (NASDAQ: APTX) increased by over 4% pre-market. This is why it happened.
Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
06:57am, Tuesday, 06'th Apr 2021
Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2020 Results - Earnings Call Transcript
10:18pm, Wednesday, 24'th Mar 2021
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2020 Results - Earnings Call Transcript
Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates
06:17pm, Wednesday, 24'th Mar 2021
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Aptinyx: Q4 Earnings Insights
05:45pm, Wednesday, 24'th Mar 2021
Shares of Aptinyx (NASDAQ:APTX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 51.22% year over year to ($0.20), which beat the esti
Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
01:38pm, Wednesday, 17'th Mar 2021
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
08:31am, Tuesday, 02'nd Mar 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference
08:30am, Thursday, 11'th Feb 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
08:37am, Tuesday, 05'th Jan 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
